• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHOU Ping, LI Li, WU Lulu, GU Chenhao, TIAN Huimin, REN Xiaoming, ZHANG Haijun, WU Jiaquan. Determination of osimertinib mesylate by HPLC[J]. Journal of China Pharmaceutical University, 2017, 48(3): 322-327. DOI: 10.11665/j.issn.1000-5048.20170312
Citation: ZHOU Ping, LI Li, WU Lulu, GU Chenhao, TIAN Huimin, REN Xiaoming, ZHANG Haijun, WU Jiaquan. Determination of osimertinib mesylate by HPLC[J]. Journal of China Pharmaceutical University, 2017, 48(3): 322-327. DOI: 10.11665/j.issn.1000-5048.20170312

Determination of osimertinib mesylate by HPLC

More Information
  • To establish an HPLC method to determine osimertinib mesylate, Agilent ZORBAX Eclipse Plus C18 column(4. 6 mm × 250 mm, 5 μm)was used with a mobile phase consisting of methanol-buffer solution(20 mmol/L NaH2PO4, pH 3. 0 adjusted with 85% H3PO4)(50 ∶50)at the flow rate of 1. 0 mL/min. The detection wavelength was 210 nm, and the column temperature was kept at 35 ℃. The calibration curve was liner over the range from 50% to 150% of determination concentration(0. 201 1- 0. 603 2 mg/mL, r=0. 999 9). The limit of quantitation(LOQ)and limit of detection(LOD)were 0. 32 μg/mL and 0. 08 μg/mL, respectively. The contents of osimertinib mesylate in samples were 100. 1%, 99. 5% and 99. 7%. Good chromatographic separation of osimertinib mesylate and its related substances, including synthetic impurities and degradation products, were obtained. The established HPLC method is specific, accurate, simple and durable, and could be used for the determination of osimertinib mesylate.
  • [1]
    Cross DA,Ashton SE,Ghiorghiu S,et al.AZD9291,an irreversible EGFR TKI,overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J].Cancer Discov,2014,4(9):1046-1061.
    [2]
    Kobayashi S,Boggon TJ,Dayaram T,et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005,352(8):786-792.
    [3]
    Yang X,Liangan C.Advances in primary resistance to EGFR-TKI in patients with non-small cell lung cancer[J].Acad J Chin PLA Med Sch(解放军医学院学报),2013,34(4):418-420.
    [4]
    Jiang T,Zhou C.Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer[J].Trans Lung Cancer Res,2014,3(6):370-372.
    [5]
    U.S.Food and Drug Administration.FDA approves new pill to treat certain patients with non-small cell lung cancer[EB/OL].https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm.
    [6]
    Liu H,Lyu Y,Li Y,et al.A novel and efficient synthesis of anti-cancer agent,mereletinib[J].J Chem Res,2015,39(6):318-320.
    [7]
    Butterworth S,Finlay MR,Ward RA,et al.Preparation of 2-(2,4,5-substituted-anilino)pyrimidine derivatives as EGFR modulators useful for treating cancer:WO,2013/14448[P].2012-07-25[2013-01-31] .
    [8]
    Rood JJ,van Bussel MT,Schellens JH,et al.Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib(AZD9291)in human plasma[J].J Chromatogr B,2016,1031:80-85.

Catalog

    Article views (2432) PDF downloads (3485) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return